LLY

745.41

-0.55%↓

JNJ

153.49

+0.9%↑

UNH

320.87

+2.66%↑

ABBV

184.64

-0.12%↓

NVO

67.92

+1.91%↑

LLY

745.41

-0.55%↓

JNJ

153.49

+0.9%↑

UNH

320.87

+2.66%↑

ABBV

184.64

-0.12%↓

NVO

67.92

+1.91%↑

LLY

745.41

-0.55%↓

JNJ

153.49

+0.9%↑

UNH

320.87

+2.66%↑

ABBV

184.64

-0.12%↓

NVO

67.92

+1.91%↑

LLY

745.41

-0.55%↓

JNJ

153.49

+0.9%↑

UNH

320.87

+2.66%↑

ABBV

184.64

-0.12%↓

NVO

67.92

+1.91%↑

LLY

745.41

-0.55%↓

JNJ

153.49

+0.9%↑

UNH

320.87

+2.66%↑

ABBV

184.64

-0.12%↓

NVO

67.92

+1.91%↑

Search

MacroGenics Inc

Open

SectorGezondheidszorg

1.56 -1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.54

Max

1.61

Belangrijke statistieken

By Trading Economics

Inkomsten

-72M

-15M

Verkoop

-93M

18M

K/W

Sectorgemiddelde

38.83

56.602

EPS

-0.818

Winstmarge

-86.977

Werknemers

341

EBITDA

-71M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+183.02% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-87M

100M

Vorige openingsprijs

2.83

Vorige sluitingsprijs

1.56

Nieuwssentiment

By Acuity

50%

50%

198 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

MacroGenics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2025, 20:40 UTC

Acquisities, Fusies, Overnames

FedEx Names CEO, Chairman for Planned Freight Spinoff

20 mei 2025, 00:00 UTC

Top Nieuws

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19 mei 2025, 23:48 UTC

Marktinformatie

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19 mei 2025, 23:43 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

19 mei 2025, 23:22 UTC

Top Nieuws

Crypto Billionaire Accused of Defrauding Creditors, Propelling Industry's 2022 Collapse -- WSJ

19 mei 2025, 22:33 UTC

Marktinformatie

Uranium Buyers Could Accelerate Restocking -- Market Talk

19 mei 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19 mei 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell Stake for CNY4.15B

19 mei 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell Stake to China Resources Land

19 mei 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q Rev $1.9B >TCOM

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q Adj EPS 82c >TCOM

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q EPS 84c >TCOM

19 mei 2025, 21:58 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

19 mei 2025, 21:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2025, 21:58 UTC

Marktinformatie

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19 mei 2025, 21:50 UTC

Top Nieuws
Winsten

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 mei 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

19 mei 2025, 20:48 UTC

Top Nieuws

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19 mei 2025, 20:20 UTC

Top Nieuws

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19 mei 2025, 20:15 UTC

Acquisities, Fusies, Overnames

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19 mei 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

19 mei 2025, 19:59 UTC

Top Nieuws

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19 mei 2025, 19:58 UTC

Marktinformatie

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19 mei 2025, 19:52 UTC

Marktinformatie

Imports Accelerate at Southern California Ports -- Market Talk

Peer Vergelijking

Prijswijziging

MacroGenics Inc Prognose

Koersdoel

By TipRanks

183.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD  183.02%

Hoogste 8 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor MacroGenics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

2

Buy

5

Hold

0

Sell

Technische score

By Trading Central

1.47 / 1.64Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

198 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.